Fennec Pharmaceuticals Inc.
FENC
$9.04
$0.364.15%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.30% | 10.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.30% | 10.42% | |||
| Cost of Revenue | 159.25% | -44.25% | |||
| Gross Profit | 3.66% | 15.46% | |||
| SG&A Expenses | 24.40% | 11.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.55% | 7.90% | |||
| Operating Income | -238.12% | 13.49% | |||
| Income Before Tax | -170.56% | 28.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -170.56% | 41.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -170.56% | 41.31% | |||
| EBIT | -238.12% | 13.49% | |||
| EBITDA | -246.16% | 13.97% | |||
| EPS Basic | -169.91% | 41.63% | |||
| Normalized Basic EPS | -169.70% | 25.21% | |||
| EPS Diluted | -169.91% | 47.97% | |||
| Normalized Diluted EPS | -169.70% | 25.21% | |||
| Average Basic Shares Outstanding | 0.31% | 0.43% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||